A Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of the Vaccine Candidates LEISH-F3 + GLA-SE, LEISH-F3 + MPL-SE, and LEISH-F3 + SE in Healthy Adult Subjects

Trial Profile

A Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of the Vaccine Candidates LEISH-F3 + GLA-SE, LEISH-F3 + MPL-SE, and LEISH-F3 + SE in Healthy Adult Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 06 Jan 2017

At a glance

  • Drugs Glycopyranosyl lipid adjuvant (Primary) ; LEISH-F3 peptide vaccine (Primary) ; Monophosphoryl lipid A (Primary) ; Squalene (Primary)
  • Indications Leishmaniasis
  • Focus Adverse reactions
  • Most Recent Events

    • 05 Jun 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 08 Jan 2015 According to the ClinicalTrials.gov record, planned end date changed from 1 Sep 2014 to 1 Jan 2015.
    • 08 Jan 2015 According to the ClinicalTrials.gov record, planned primary completion date changed from 1 Sep 2014 to 1 Jan 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top